FK 778 | CAS#185915-33-7 | antirheumatic

MedKoo Cat#: 584722 | Name: FK 778

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FK 778 is a derivative of A77 1726, the active metabolite of the antirheumatic drug leflunomide, where the isoxazole ring has opened to become a nitrile and an alkyne.

Chemical Structure

FK 778

CAS#185915-33-7

Theoretical Analysis

MedKoo Cat#: 584722

Name: FK 778

CAS#: 185915-33-7

Chemical Formula: C15H11F3N2O2

Exact Mass: 308.0773

Molecular Weight: 308.26

Elemental Analysis: C, 58.45; H, 3.60; F, 18.49; N, 9.09; O, 10.38

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

FK 778; FK-778; HMR 1715; HMR-1715; MNA 715; MNA-X 920715; X 920715; X-920715

IUPAC/Chemical Name

2-Hepten-6-ynamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-

InChi Key

IRELROQHIPLASX-SEYXRHQNSA-N

InChi Code

InChI=1S/C15H11F3N2O2/c1-2-3-4-13(21)12(9-19)14(22)20-11-7-5-10(6-8-11)15(16,17)18/h1,5-8,21H,3-4H2,(H,20,22)/b13-12-

SMILES Code

C#CCC/C(O)=C(C#N)/C(NC1=CC=C(C(F)(F)F)C=C1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 308.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kaplan MJ. FK-778 Astellas. Curr Opin Investig Drugs. 2005 May;6(5):526-36. Review. PubMed PMID: 15912968. 2: Bloudícková S, Rajnoch J, Lodererová A, Honsová E, Viklický O. Leflunomide derivate FK 778 in accelerated renal injury in transgenic rat. Folia Biol (Praha). 2010;56(2):72-7. PubMed PMID: 20492759. 3: Wlodarczyk Z, Vanrenterghem Y, Krämer BK, Squifflet JP, Ostrowski M. A multicenter, randomized, double-blind study comparing different FK778 doses (manitimus) with tacrolimus and steroids vs. MMF with tacrolimus and steroids in renal transplantation. BMC Nephrol. 2012 Jul 26;13:68. doi: 10.1186/1471-2369-13-68. PubMed PMID: 22835011; PubMed Central PMCID: PMC3418183. 4: Zonta S, Alessiani M, Viganò J, Doni M, Bardone M, Dominioni T, De Martino M, Scaglione M, Vicini E, Filisetti C, Biroli A, Bottazzi A, Villa C, Morbini P, Dionigi P. Prolonged survival with FK778 (malononitrilamide) monotherapy after small bowel transplantation: a large animal study. Transplant Proc. 2007 Jul-Aug;39(6):2021-3. PubMed PMID: 17692681. 5: Bîrsan T, Dambrin C, Klupp J, Stalder M, Larson MJ, Fitzsimmons WE, Morris RE. In vivo pharmacokinetic and pharmacodynamic evaluation of the malononitrilamide FK778 in non-human primates. Transpl Int. 2003 May;16(5):354-60. Epub 2003 Apr 24. PubMed PMID: 12712238. 6: Alessiani M, Abbiati F, Zonta S, Zitelli E, Bardone M, Cobianchi L, Viganò J, Doni M, Mazzilli M, Dominioni T, Kabiri D, Bottazzi A, Morbini P, Molinaro MD, Dionigi P. FK778 and tacrolimus combination therapy to control acute rejection after pig intestinal transplantation. Transplant Proc. 2006 Jul-Aug;38(6):1809-11. PubMed PMID: 16908288. 7: Deuse T, Hoyt G, Koyanagi T, Robbins RC, Schrepfer S. Prevention and inhibition but not reversion of chronic allograft vasculopathy by FK778. Transplantation. 2008 Mar 27;85(6):870-7. doi: 10.1097/TP.0b013e3181673608. PubMed PMID: 18360270. 8: Deuse T, Schrepfer S, Pelletier MP, Fischbein MP, Robbins RC, Reichenspurner H. Is the malononitrilamide FK778 better for the prevention of acute or chronic rejection? Transplant Proc. 2007 Mar;39(2):569-72. PubMed PMID: 17362784. 9: Kreijveld E, Koenen HJ, Hilbrands LB, van Hooff HJ, Joosten I. The immunosuppressive drug FK778 induces regulatory activity in stimulated human CD4+ CD25- T cells. Blood. 2007 Jan 1;109(1):244-52. Epub 2006 Aug 10. PubMed PMID: 16902146. 10: Fischereder M, Kretzler M. New immunosuppressive strategies in renal transplant recipients. J Nephrol. 2004 Jan-Feb;17(1):9-18. Review. PubMed PMID: 15151254. 11: Vu MD, Qi S, Wang X, Jiang W, Ma A, Xu D, Bekersky I, Fitzsimmons WE, Wu J, Chen H. Combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays and in rats receiving renal allografts. Transplantation. 2003 May 15;75(9):1455-9. PubMed PMID: 12792496. 12: Hoppe-Seyler K, Sauer P, Lohrey C, Hoppe-Seyler F. The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro. Hepatology. 2012 Jul;56(1):9-16. doi: 10.1002/hep.25602. Epub 2012 Jun 1. PubMed PMID: 22271223. 13: Guasch A, Roy-Chaudhury P, Woodle ES, Fitzsimmons W, Holman J, First MR; FK778 BK Nephropathy Study Group. Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. Transplantation. 2010 Oct 27;90(8):891-7. doi: 10.1097/TP.0b013e3181f2c94b. PubMed PMID: 20811320. 14: Deuse T, Schrepfer S, Reichenspurner H. The interaction between FK778 and tacrolimus in the prevention of rat cardiac allograft rejection is dose dependent. Transplantation. 2004 Feb 27;77(4):509-13. PubMed PMID: 15084926. 15: Jin MB, Nakayama M, Ogata T, Fujita M, Mino K, Taniguchi M, Suzuki T, Shimamura T, Furukawa H, Todo S. A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. Surgery. 2002 Jul;132(1):72-9. PubMed PMID: 12110798. 16: Kyles AE, Gregory CR, Griffey SM, Bernsteen L, Pierce J, Lilja HS, Morris RE. Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs. Transplantation. 2003 Apr 27;75(8):1128-33. PubMed PMID: 12717190. 17: Fitzsimmons WE, First MR. FK778, a synthetic malononitrilamide. Yonsei Med J. 2004 Dec 31;45(6):1132-5. Review. PubMed PMID: 15627308. 18: Schorlemmer HU, Ruuth E, Kurrle R. Regulation of alloreactivity in the popliteal lymph node assay by the new immunosuppressants: malononitrilamides. Transpl Int. 1998;11 Suppl 1:S448-51. PubMed PMID: 9665036. 19: Schorlemmer HU, Kurrle R, Bartlett RR. The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodents. Drugs Exp Clin Res. 1997;23(5-6):167-73. PubMed PMID: 9515226. 20: Alessiani M, Zonta S, Abbiati F, Cobianchi L, Bardone M, Zitelli E, Doni M, Viganò J, Mazzilli M, Lovisetto F, Dominioni T, Dionigi B, Lusona B, Morbini P, Molinaro MD, Dionigi P. Efficacy of malononitrilamide FK778 in a preclinical model of small bowel transplantation. Transplant Proc. 2005 Jul-Aug;37(6):2719-21. PubMed PMID: 16182793.